CSF2 and melanoma: In 2019, they reported the final results of the OPTiM research.320 A total of 436 patients with advanced melanoma were enrolled in the research and were arranged randomly into the group of the T-VEC treatment (n = 295) or the GM-CSF treatment (n = 141).